Development of peptidic MERS-CoV entry inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1513-1519, 2015.
Artículo
en Chino
| WPRIM
| ID: wpr-320049
ABSTRACT
In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Péptidos
/
Farmacología
/
Fisiología
/
Diseño de Fármacos
/
Infecciones por Coronavirus
/
Dipeptidil Peptidasa 4
/
Quimioterapia
/
Internalización del Virus
/
Glicoproteína de la Espiga del Coronavirus
Límite:
Humanos
Idioma:
Chino
Revista:
Acta Pharmaceutica Sinica
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS